News Headline Summary

Johnson & Jonhson's (JNJ) Zytiga approved in EU for treatment of Metastatic Castration-resistant Prostate cancer before chemotherapy

Reaction details (15:41)

- Co. shares are unmoved in reaction to the news; trades USD 72.45 (+0.36%) last.

11 Jan 2013 - 15:39 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: